Efficacy of sulodexide, low-molecular heparin, in therapy of diabetic nephropathy

M. V. Shestakova, L. A. Chugunova, A. V. Vorontsov, I. I. Dedov

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


A novel pathogenetic approach to treatment of diabetic nephropathy (DN) as a severe complication of diabetes mellitus is aimed at inhibiting DN progression or its involution by means of reestablishment of heparansulfate synthesis by glycosaminoglycane drug. In the study of 9 patients with microalbuminuria and 9 with proteinuria this drug was low-molecular heparin - sulodexide (Alfa-Wasserman, Italy). The treatment course of 3 weeks resulted in albuminuria fall in 89% of patients. In patients with microalbuminuna protein excretion returned to normal values in a week of treatment. This effect was persistent after the drug discontinuation. This was not so for protein excretion in proteinuria patients which became low after 3 weeks of treatment, but the effect was not long-lasting. The authors believe that glycosaminoglycanes hold great promise in DN, especially at early stages of renal diabetic affection.

Original languageEnglish
Pages (from-to)34-37
Number of pages4
JournalTerapevticheskii Arkhiv
Issue number6
StatePublished - 1997


Dive into the research topics of 'Efficacy of sulodexide, low-molecular heparin, in therapy of diabetic nephropathy'. Together they form a unique fingerprint.

Cite this